Zheng Xiaoqin, Li Lanjuan
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Infect Microbes Dis. 2020 Jul 16;2(3):89-95. doi: 10.1097/IM9.0000000000000033. eCollection 2020 Sep.
The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.
最近出现的2019冠状病毒病（COVID-19）已迅速演变成一场大流行，感染人数超过1000万，死亡人数超过50万。目前尚无有效的疗法或疫苗可预防这种冠状病毒感染。在本综述中，我们根据先前对严重急性呼吸综合征（SARS）和中东呼吸综合征（MERS）的研究所得的现有信息，讨论针对COVID-19的潜在治疗选择。目前正在大力研发针对COVID-19的新型治疗药物，包括重新利用现有药物以及开发专门针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）或宿主因子的新型药物。通过筛选化合物库，已确定多种药物，如利巴韦林、瑞德西韦、洛匹那韦/利托那韦和羟氯喹，为针对COVID-19的潜在治疗候选药物。正在研发针对严重急性呼吸综合征冠状病毒2的新型抗病毒药物，以靶向病毒酶或功能蛋白以及宿主因子或细胞信号通路。
